Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price78.13 USD
Fair value67.04
Ethical score70.0/100
Our investment reviews on this name
2026-09-03Read Accumulation78.68-0.7% to today
2026-08-04Read Markup63.95+22.2% to today ✓
2026-07-02Read Distribution51.89+50.6% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Kiniksa Pharmaceuticals International, plc holds its Markdown at $78.13. The statistical read favours the sellers, held for 21 days.
As held on the ledger · 2026-09-21
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 21 days
Price at the screen
$78.13
Valuation
78.92 trailing · 48.30 forward price to earnings
Values screen
PASS· score 70.0
Beta
0.09
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
1.24%
Below 33%
Interest-bearing debt is just 1.2% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
32.54%
Below 33%
Cash held in interest-bearing accounts and securities is 32.5% of assets, under the one-third limit.
Pass
Receivables
23.73%
Below 49%
Money owed to the company is 23.7% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-21 screen. The gold marker is the market price at the same screen. The price runs 14.2% above the base estimate.
Third-party analyst targets: 8 covering, consensus None. The average target sits +26% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-21 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
High growth drug maker priced above its worth
Every patient who gets relief from a new therapy like ARCALYST shows how specialist drug developers can move fast. Kiniksa has posted 56 percent revenue growth, a 10 percent profit margin and 14 percent return on equity, yet the shares trade at 63.95 dollars against a fair value of 52.98 dollars. That leaves a negative margin of safety and a forward multiple of 37.6 times earnings.
We pass. The strong buy consensus and 68 dollar median target already assume the growth story runs without a hitch, but nothing in the numbers suggests the current price offers any cushion if momentum fades.
Risks sit in typical biotech execution, competition and the chance that peak sales fall short of lofty expectations. Currency and regulatory shifts add further uncertainty in this field. Analysis, not advice.
The risks · The things to watch: its business and earnings are exposed to United Kingdom and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KNSA trades on Nasdaq (the company is based in United Kingdom). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 23.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $64.
2026-08-04Markup · changed$63.95+23.2%Entry 4
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 23.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $64.
2026-07-18Distribution$51.89+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 67%. Our forward projection puts the odds of a 10% gain over the next month near 38%. The street (8 analysts) rates it none, with a mean price target of $64.
2026-07-03Distribution$51.89+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
2026-07-02Distribution$51.89Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows excellent risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
